Alnylam Pharmaceuticalsvs.Amgen
ALNY vs AMGN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Amgen is about 4.9× larger than Alnylam Pharmaceuticals by market cap; Amgen trades at the lower P/E (25.1 vs 69.1); year to date, Amgen leads (+11.0% vs −24.9%).
Side by side
| ALNY | AMGN | |
|---|---|---|
| Market cap | $39.9B | $196B |
| Price | $298.76 | $363.39 |
| Today | −4.5% | −0.1% |
| Return YTD | −24.9% | +11.0% |
| Return 1Y | −7.4% | +21.0% |
| P/E | 69.1 | 25.1 |
| P/S | 9.3 | 5.3 |
| P/B | 37.1 | 21.3 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Alnylam PharmaceuticalsALNY
Pioneer of RNAi medicines for rare and cardiovascular diseases.
Full ALNY profile →AmgenAMGN
Veteran American biotech with a broad portfolio in oncology, immunology and bone diseases — and an obesity candidate (MariTide) in the pipeline.
Full AMGN profile →More comparisons in Biotech & innovation
See where ALNY and AMGN sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →